Tags

Type your tag names separated by a space and hit enter

Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy.
J Neurol Sci. 2006 Oct 25; 248(1-2):56-61.JN

Abstract

Both methylenetetrahydrofolate (MTHFR) C677T genotype and levodopa treatment may give rise to elevated serum homocysteine levels in parkinsonian patients. We aimed to clarify the interplay of these factors in pathogenesis of Parkinson's disease (PD)-related hyperhomocysteinemia. Total serum levels of homocysteine (tHcy) and MTHFR C677T genotype were investigated in levodopa-treated and -untreated parkinsonian ("de novo") patients, as well as in control healthy subjects matched by age and gender (N=83, 30 and 53, respectively). MTHFR C677T genotypes were equally distributed in PD patients and control subjects, the T allele homozygosity being observed in app. 12-17% cases. tHcy concentrations were significantly higher in both levodopa-treated and -untreated PD patients than in control subjects, and in TT homozygotes than in CT or CC genotype carriers. tHcy levels significantly correlated with the duration of the disease in PD treated patients only, reaching the maximum after 3-6 years. However, there was no correlation between tHcy levels and total daily intake of levodopa in the same group of PD patients. In conclusion, MTHFR C677T genotype is a significant factor for hyperhomocysteinemia in patients with PD, levodopa-untreated and probably even more in levodopa-treated PD patients.

Authors+Show Affiliations

Todorović Z
Department of Pharmacology, Clinical Pharmacology and Toxicology, School of Medicine, University of Belgrade, P.O. Box 840, ul. Dr. Subotića 1, 11129 Belgrade, Serbia and Montenegro. ztodorovic@med.bg.ac.yu
Dzoljić E
No affiliation info available
Novaković I
No affiliation info available
Mirković D
No affiliation info available
Stojanović R
No affiliation info available
Nesić Z
No affiliation info available
Krajinović M
No affiliation info available
Prostran M
No affiliation info available
Kostić V
No affiliation info available

MeSH

AdultAgedAged, 80 and overAntiparkinson AgentsCysteineFemaleHomocysteineHumansLevodopaMaleMethylenetetrahydrofolate Reductase (NADPH2)Middle AgedParkinson DiseaseThreonineTime Factors

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article

Language

eng

PubMed ID

16774768

Citation

Todorović, Zoran, et al. "Homocysteine Serum Levels and MTHFR C677T Genotype in Patients With Parkinson's Disease, With and Without Levodopa Therapy." Journal of the Neurological Sciences, vol. 248, no. 1-2, 2006, pp. 56-61.
Todorović Z, Dzoljić E, Novaković I, et al. Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy. J Neurol Sci. 2006;248(1-2):56-61.
Todorović, Z., Dzoljić, E., Novaković, I., Mirković, D., Stojanović, R., Nesić, Z., Krajinović, M., Prostran, M., & Kostić, V. (2006). Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy. Journal of the Neurological Sciences, 248(1-2), 56-61.
Todorović Z, et al. Homocysteine Serum Levels and MTHFR C677T Genotype in Patients With Parkinson's Disease, With and Without Levodopa Therapy. J Neurol Sci. 2006 Oct 25;248(1-2):56-61. PubMed PMID: 16774768.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy. AU - Todorović,Zoran, AU - Dzoljić,Eleonora, AU - Novaković,Ivana, AU - Mirković,Dusko, AU - Stojanović,Radan, AU - Nesić,Zorica, AU - Krajinović,Maja, AU - Prostran,Milica, AU - Kostić,Vladimir, Y1 - 2006/06/13/ PY - 2006/6/16/pubmed PY - 2007/1/24/medline PY - 2006/6/16/entrez SP - 56 EP - 61 JF - Journal of the neurological sciences JO - J Neurol Sci VL - 248 IS - 1-2 N2 - Both methylenetetrahydrofolate (MTHFR) C677T genotype and levodopa treatment may give rise to elevated serum homocysteine levels in parkinsonian patients. We aimed to clarify the interplay of these factors in pathogenesis of Parkinson's disease (PD)-related hyperhomocysteinemia. Total serum levels of homocysteine (tHcy) and MTHFR C677T genotype were investigated in levodopa-treated and -untreated parkinsonian ("de novo") patients, as well as in control healthy subjects matched by age and gender (N=83, 30 and 53, respectively). MTHFR C677T genotypes were equally distributed in PD patients and control subjects, the T allele homozygosity being observed in app. 12-17% cases. tHcy concentrations were significantly higher in both levodopa-treated and -untreated PD patients than in control subjects, and in TT homozygotes than in CT or CC genotype carriers. tHcy levels significantly correlated with the duration of the disease in PD treated patients only, reaching the maximum after 3-6 years. However, there was no correlation between tHcy levels and total daily intake of levodopa in the same group of PD patients. In conclusion, MTHFR C677T genotype is a significant factor for hyperhomocysteinemia in patients with PD, levodopa-untreated and probably even more in levodopa-treated PD patients. SN - 0022-510X UR - https://www.unboundmedicine.com/medline/citation/16774768/Homocysteine_serum_levels_and_MTHFR_C677T_genotype_in_patients_with_Parkinson's_disease_with_and_without_levodopa_therapy_ DB - PRIME DP - Unbound Medicine ER -